

NANOPARTICLES IN DRUG DELIVERY: A TRANSFORMATIVE APPROACH FOR ENHANCED THERAPEUTIC OUTCOMES

1 Sayli Saw, 2 Varma Vishnu, 3 Harshul Parmar, 4 Sanjesh Rathi, 5 Shubham Singh, and 6 Arun Kumar Chaturvedi

1, 2, 3, 4, & 5 School of Pharmacy, Rai University, Ahmedabad, Gujarat, India.
6 Sainath College of Pharmacy, Sonbhadra, Uttar Pradesh, India.

ABSTRACT:

Nanoparticles have become an essential tool in physiology and medicine, offering precise drug delivery solutions with enhanced targeting, controlled release, and improved therapeutic efficacy. This review examines the role of polymeric nanoparticles in advancing drug delivery systems, focusing on production techniques such as solvent evaporation, emulsification, nanoprecipitation, and coacervation, each with distinct advantages and limitations for encapsulating diverse therapeutic agents. Key nanoparticle properties such as particle size, surface charge, and morphology are analyzed in relation to their impact on pharmacokinetics, biodistribution, and compatibility with physiological environments. The review places particular emphasis on applications for poorly soluble drugs, as nanoparticle formulations can significantly enhance bioavailability and therapeutic outcomes, addressing critical challenges in drug development. By aligning nanoparticle design with physiological principles, this paper provides a comprehensive overview of the potential for nanoparticles to revolutionize therapeutic delivery in clinical settings, ultimately supporting the development of more effective treatments in both physiological research and medical practice.

KEYWORDS: Nanoparticles, Preparation, Drug Delivery, Targeting, Drug Release, Supercritical Antisolvent Method, Drug Encapsulation.

1. INTRODUCTION:

Nanoparticles are defined as solid or dispersed particles with sizes ranging from 10 to 1,000 nanometers. In these systems, drugs can be dissolved, encapsulated, enclosed, or attached within the nanoparticle matrix [1]. Based on the production technique, either nanoparticles or Nanocapsules can be formed. Nanocapsules are systems where the drug is confined within a cavity surrounded by a polymer membrane, whereas nanoparticles distribute the drug evenly throughout a matrix structure [18-20]. Recently, biodegradable polymer nanoparticles, particularly those coated with hydrophilic polymers like poly (ethylene glycol) (PEG), have emerged as effective drug delivery vehicles due to their prolonged circulation time, organ-targeting abilities, DNA-carrying potential for gene therapy, and capacity to deliver proteins, peptides, and genes. The primary objectives in designing nanoparticle delivery systems are to control particle size, surface properties, and drug release, aiming for targeted therapeutic effects and optimal dosing [2].

Advantages:

- Nanoparticle particle size and surface properties can be modified with ease.
- They regulate drug release during transport and localization, guiding the drug's distribution and later removal to enhance therapeutic impact and reduce side effects.
- Adjusting the substrate composition can fine-tune the controlled release and degradation characteristics of nanoparticles. The drug loading capacity is relatively high, and drugs can be integrated without chemical alteration.
- Targeted drug delivery is achievable through ligand attachment on particle surfaces or magnetic guidance.
- This system supports multiple administration routes, such as oral, nasal, parenteral, and intraocular.

Limitations:

- Due to their small size and large surface area, nanoparticles may aggregate, complicating their handling in both liquid and dry forms.
- Furthermore, this small size and high surface area can limit drug delivery, often resulting in uneven release.

Before nanoparticles can be fully adopted in clinical and commercial production, certain technical challenges must be addressed. Many marketed drugs exhibit poor water solubility [3], posing significant obstacles in pharmaceutical formulation due to issues such as low oral bioavailability and unpredictable absorption patterns [4]. Factors like water solubility, the

physiological environment, and intestinal permeability are critical in determining the fraction of the drug dose that is absorbed. For drugs with high intestinal permeability, dissolution often serves as a rate-limiting factor. Strategies to enhance solubility kinetics include reducing particle size to increase surface area [5], coating particles with hydrophilic surfactants to improve wettability and solvation in the intestinal environment [6], utilising solid dispersion techniques [7], and converting crystalline drugs into their amorphous forms [8]. According to the Noyes-Whitney and Ostwald-Freundlich equations, reducing particle size can significantly enhance dissolution rates [9].

2. METHODS FOR PRODUCING POLYMERIC NANOPARTICLES:

Various production techniques are available, depending on the drug being incorporated into polymeric nanoparticles (NPs) and the intended route of administration. Generally, two main approaches are employed: the dispersion of preformed polymers or the polymerization of monomers.

In methods using preformed polymers, organic solvents are commonly employed in the initial step to dissolve the polymer, though this can lead to challenges with toxicity and environmental impact, requiring solvent residue removal from the final product. Polymerization-based methods for producing nanoparticles enable the direct incorporation of compounds with higher efficiency in a single reaction step [10].

2.1. Solvent Evaporation

Solvent evaporation is one of the earliest methods developed for producing polymeric NPs from preformed polymers. This technique begins by preparing an oil-in-water emulsion, which subsequently generates nanoparticles (Figure 1). An organic phase is first created, consisting of a polar organic solvent that dissolves the polymer, with the drug incorporated into the solution. Commonly used solvents include dichloromethane and chloroform, with the former being more frequently used; however, due to their toxicity, safer alternatives like ethyl acetate are now preferred in biomedical applications.

In this process, an aqueous phase containing a surfactant, such as polyvinyl acetate (PVA), is prepared alongside the organic solution, which is then emulsified within the aqueous phase. Emulsification is typically enhanced through homogenization or high-speed sonication, promoting nanoparticle dispersion. Nanoparticle suspensions are formed by evaporating the polymeric solvent, which diffuses through the emulsion's continuous phase. Solvent removal is achieved by magnetic stirring at room temperature (for more polar solvents) or a gradual process at reduced pressure (as in the case of dichloromethane or chloroform). Once the solvent

evaporates, the solidified nanoparticles are collected by centrifugation, washed, and lyophilized for long-term storage. Commonly used polymers in this method include PLA, poly(β -hydroxybutyrate) (PHB), poly(caprolactone) (PCL), PLGA, cellulose acetate phthalate, and EC [11].

Advantages:

High entrapment efficiency for lipophilic drugs.

Particle size can be tailored by adjusting homogenization speed, stabilizer quantity, and the viscosity of the organic and aqueous phases.

Disadvantages:

Limited entrapment efficiency for hydrophilic drugs.

Scale-up challenges for large-scale production.




Figure 1: Schematic diagram of solvent evaporation method.

2.2. Emulsification/Solvent Diffusion

This method involves creating an oil-in-water (o/w) emulsion between a solvent containing both the polymer and drug and an aqueous solution with surfactants (Figure 2). The internal phase of this emulsion comprises an organic solvent, partially water-soluble (e.g., benzyl alcohol or ethyl acetate), which is pre-saturated with water to establish thermodynamic equilibrium between the two phases at room temperature. By diluting with a large volume of water, the organic solvent diffuses from the dispersed droplets into the surrounding aqueous phase, leading to the formation of colloidal particles. While this technique primarily produces

nanospheres, Nanocapsules can also be generated by adding small amounts of oils (such as triglycerides: C6, C8, C10, or C12) to the organic phase.

The final step, depending on the boiling point of the organic solvent, can be either solvent evaporation or filtration. The resulting nanoparticles typically range in size from 80 to 900 nm. This method is commonly used for producing macromolecular NPs, despite the high volume of aqueous phase required and the potential for hydrophilic drug diffusion into this phase. Examples of drugs successfully incorporated using this method include cyclosporine (CyA), charged sodium glycolate nanoparticles, and doxorubicin-loaded PLGA nanoparticles [12].

Advantages:

- Suitable for incorporating thermosensitive drugs.
- Reduces average particle size with narrow size distribution.
- Provides good batch-to-batch consistency.
- High entrapment efficiency for lipophilic drugs.
- Use of non-toxic solvents.
- Scalable to larger production volumes.

Disadvantages:

- The final formulation requires concentration.
- Potential for residual organic solvents in the end product.
- Poor encapsulation efficiency for hydrophilic drugs.
- Requires prolonged emulsion agitation.
- Demands a large water volume for nanoparticle formation.




Figure 2: Schematic diagram of emulsion-solvent diffusion method

2.3. Emulsification/Reverse Salting-Out

The reverse salting-out method produces nanoparticles through the separation of water-soluble solvents from aqueous solutions using a salting effect. Unlike other emulsification techniques, the oil-in-water (o/w) emulsion here consists of a water-soluble polymeric solvent, such as acetone or ethanol, combined with an aqueous phase containing a gel, a salting agent, and a colloidal stabilizer. Suitable salting agents include electrolytes like magnesium chloride (MgCl_2), calcium chloride (CaCl_2), or magnesium acetate [$\text{Mg}(\text{CH}_3\text{COO})_2$], as well as non-electrolytes such as sucrose.

The aqueous phase is saturated to decrease acetone's miscibility with water, which allows the formation of o/w emulsions with other combinations. After preparing the o/w emulsion with vigorous stirring at room temperature, it is diluted with demineralized water. This dilution allows the organic solvent to diffuse into the outer phase, leading to polymer precipitation and nanoparticle formation. Tangential filtration is then used to remove residual solvents and salting agents. Although complete miscibility between organic solvents and water isn't essential, it simplifies the process. Nanoparticles formed by this method typically range from 170 to 900 nm in size, with average sizes adjustable between 200 and 500 nm by modifying the polymer concentration in the internal phase and the external phase volume (Figure 3) [13].

Advantages:

- High efficiency and scalability for producing nanoparticles of ethyl cellulose, PLA, and poly (methacrylic acid).
- No heating is required.
- No high shear stress is needed, suitable for heat-sensitive drugs.
- High loading efficiency for lipophilic drugs.
- Easy to scale up.
- Excellent reproducibility.

Disadvantages:

- Requires extensive washing of nanoparticles.
- Only suitable for lipophilic drugs.




Figure 3: Schematic diagram of reverse salting out method

2.4. Nanoprecipitation

Also known as the solvent displacement method, nanoprecipitation involves mixing two solvents to create nanoparticles. The internal phase contains a polymer dissolved in a water-miscible organic solvent, such as acetone or acetonitrile, which can be easily removed by evaporation since they do not dissolve in water. This technique relies on the surface deposition of a polymer when the organic solvent transitions from a lipophilic solution into the aqueous phase. In this process, the polymer is dissolved in an intermediate-polarity, water-soluble solvent, and the solution is added dropwise or at a controlled rate to the aqueous phase under stirring. Nanoparticles form instantly as the polymer solution diffuses into the aqueous phase, avoiding contact with water molecules.

As the solvent diffuses out, the polymer precipitates as either nanoparticles or nanocapsules, depending on the preparation. Generally, the organic phase is added to the aqueous phase, but reversing this order does not hinder nanoparticle formation. Surfactants can be added to stabilize the colloidal suspension, though they aren't strictly necessary for nanoparticle creation. Nanoprecipitation typically yields well-defined particle sizes with narrow distributions, which are more consistent than those produced by emulsification-solvent evaporation. This method is often used for creating macromolecular nanoparticles of approximately 170 nm. Nanoparticles are formed when the active ingredient is dissolved or dispersed in the polymer solution. Nanocapsules are produced if the drug is first dissolved in oil, which is then emulsified into an organic polymer solution before being added to the aqueous phase (Figure 4) [14].

Advantages:

- Simple and fast process.

- Utilizes low-toxicity solvents.
- High reproducibility across batches.
- No high-shear stress is required.
- Produces monodispersed particles.

Disadvantages:

- Primarily suited for encapsulating hydrophobic compounds.
- Nanoparticle size depends heavily on polymer concentration.




Figure 4: Schematic diagram of Nanoprecipitation method

2.5. Polymerization Method

In the polymerization method, nanoparticles are synthesized by polymerizing monomers directly in an aqueous solution. Drugs can be incorporated by dissolving them in the polymerization medium or by adsorbing them onto the nanoparticles after the polymerization process is complete (Figure 5). After synthesis, the nanoparticle suspension is purified by ultrasonic centrifugation to remove stabilizers and surfactants used during polymerization. The purified particles are then re-suspended in an isotonic medium free of surfactants. This approach is often applied to produce nanoparticles of poly butyl cyanoacrylate or poly (alkyl cyanoacrylate), with the formation of nanocapsules and particle size determined by the concentrations of surfactants and stabilizers used [15].

Advantages:

- The simple system requires minimal insulation.
- Produces a highly pure polymer product.
- Allows direct preparation of large particles.
- Easy adjustment of molecular mass distribution using a chain transfer agent.

- Fast and scalable production.

Disadvantages:

- Heat transfer and mixing become challenging as reactant viscosity increases.
- Strong heat release during the reaction.
- Polymerization results in a wide molecular weight distribution due to high viscosity and limited heat transfer.
- Yields polymers with low molecular weights.
- Involves toxic organic solvents and monomers.
- Difficult to fully remove residual monomers, initiators, and surfactants from the final product.




Figure 5: Schematic diagram of Polymerization method

2.6. Coacervation or Ionic Gelation Method

The coacervation or ionic gelation method is widely used for creating nanoparticles from biodegradable hydrophilic polymers like chitosan, gelatin, and sodium alginate. Hydrophilic chitosan nanoparticles were prepared using the ion gelation method (Figure 6) [16]. This technique involves mixing two aqueous phases: one containing a chitosan polymer and a polyethylene oxide-propylene oxide (PEO-PPO) diblock copolymer, and the other containing sodium tripolyphosphate, a polyanion. In this process, the positively charged amine groups in chitosan interact with the negatively charged tripolyphosphate ions to form nanoscale coacervates. Nanoparticle coagulation occurs due to electrostatic interactions between these aqueous phases, while the ionic gelation process allows the material to transition from a liquid to a gel state under specific ionic conditions at room temperature.

Advantages:

- Suitable for incorporating heat-sensitive drugs.

- Cost-effective for both laboratory and industrial applications.
- Enables control over the shape and size of solid lipid nanoparticles (SLNs) by adjusting reaction conditions.

Disadvantage:

- Potential degradation of components in acidic conditions.




Figure 6: Schematic diagram of Coacervation or ionic gelation method

2.7. Double Emulsion and Evaporation Method

The double emulsion and evaporation method is commonly used to encapsulate hydrophilic drugs [16]. In this approach, an aqueous solution of the drug is emulsified into an organic solution of a polymer under vigorous stirring, creating a primary (water-in-oil, or w/o) emulsion (Figure 7). This primary emulsion is then emulsified again into an aqueous phase to form a secondary (water-in-oil-in-water, or w/o/w) emulsion. Following this, the volatile solvent is removed, and high-speed centrifugation is applied to isolate the nanoparticles. The particles are washed and, if necessary, lyophilized for storage. Key variables in this method include the amount of hydrophilic drug, polymer concentration, volume of the aqueous phase, and stabilizer concentration, all of which influence nanoparticle properties.

Advantages:

- Suitable for encapsulating both hydrophilic and hydrophobic active ingredients.

Disadvantages:

- Produces large, non-uniform (polydisperse) particles.
- Involves a two-step process.
- Potential leakage of the hydrophilic active into the outer aqueous phase.
- Challenging to scale up.
- Limited entrapment efficiency for hydrophilic drugs.




Figure 7: Schematic diagram of Double Emulsion and Evaporation Method

3. CONCLUSION:

The development of nanoparticles as drug carriers holds significant promise for enhancing therapeutic outcomes by improving drug solubility, targeting specificity, and controlled release profiles. While considerable advances have been made in nanoparticle synthesis, challenges remain in achieving scalability, minimizing toxicity, and improving encapsulation efficiency for hydrophilic drugs. Future research should focus on refining these methods to meet clinical and commercial standards, potentially integrating biodegradable polymers and novel encapsulation technologies. The continued evolution of nanoparticle-based systems could play a crucial role in overcoming current limitations in drug delivery, paving the way for more effective and personalized medical treatments.

REFERENCES:

1. Kumar, S., Saha, S., Singh, K., Singh, T., Mishra, A. K., Dubey, B. N., & Singh, S. (2024). Beneficial effects of spirulina on brain health: A systematic review. *Current Functional Foods*, 3(1), Article e120124225622. <https://doi.org/10.2174/0126668629269256231222092721>
2. RaviKKumar VR, Rathi S, Singh S, Patel B, Singh S, Chaturvedi K, Sharma B. A Comprehensive Review on Ulcer and Their Treatment. *Zhongguo Ying Yong Sheng Li Xue Za Zhi*. 2023 Dec 21;39:e20230006. doi: 10.62958/j.cjap.2023.006. PMID: 38755116.
3. Singh, V., Arora, S., Akram, W., Alam, S., Kumari, L., Kumar, N., Kumar, B., Kumar, S., Agrawal, M., Singhal, M., Kumar, S., Singh, S., Singh, K., Saha, S., & Dwivedi, V. (2024). Involvement of molecular mechanism and biological activities of Pemirolast: A therapeutic review. *New Emirates Medical Journal*, 5, Article e02506882308410. <https://doi.org/10.2174/0102506882308410240607053814>
4. Rajput DS, Gupta N, Singh S, Sharma B. A Comprehensive Review: Personalized Medicine for Rare Disease Cancer Treatment. *Zhongguo Ying Yong Sheng Li Xue Za Zhi*. 2023 Dec 23;39:e20230008. doi: 10.62958/j.cjap.2023.008. PMID: 38830754.
5. Singh S, Chaurasia A, Rajput DS, Gupta N. Mucoadhesive Drug Delivery System and There Future Prospective: Are a Promising Approach for Effective Treatment? *Zhongguo Ying Yong Sheng Li Xue Za Zhi*. 2023 Dec 20;39:e20230005. doi: 10.62958/j.cjap.2023.005. PMID: 38751344.
6. Kumar, S., Saha, S., Sharma, B., Singh, S., Shukla, P., Mukherjee, S., Agrawal, M., Singh, K., & Singh, T. (2023). The role of resveratrol in Alzheimer's disease: A comprehensive review of current research. *Current Functional Foods*, 2(2), Article e121223224364, 13 pages. <https://doi.org/10.2174/0126668629269244231127071411>
7. Patel S, Ismail Y, Singh S, Rathi S, Shakya S, Patil SS, Bumrela S, Jain PC, Goswami P, Singh S. Recent Innovations and Future Perspectives in Transferosomes for Transdermal Drug Delivery in Therapeutic and Pharmacological Applications. *Zhongguo Ying Yong Sheng Li Xue Za Zhi*. 2024 Oct 24;40:e20240031. doi: 10.62958/j.cjap.2024.031. PMID: 39442957.
8. Vaghela MC, Rathi S, Shirole RL, Verma J, Shaheen, Panigrahi S, Singh S. Leveraging AI and Machine Learning in Six-Sigma Documentation for Pharmaceutical Quality Assurance. *Zhongguo Ying Yong Sheng Li Xue Za Zhi*. 2024 Jul 18;40:e20240005. doi: 10.62958/j.cjap.2024.005. PMID: 39019923.

9. Patel S, Ismail Y, Singh S, Rathi S, Shakya S, Patil SS, Bumrela S, Jain PC, Goswami P, Singh S. Recent Innovations and Future Perspectives in Transfersomes for Transdermal Drug Delivery in Therapeutic and Pharmacological Applications. *Zhongguo Ying Yong Sheng Li Xue Za Zhi*. 2024 Oct 24;40:e20240031. doi: 10.62958/j.cjap.2024.031. PMID: 39442957.
10. Kumar, S., Saha, S., Pathak, D., Singh, T., Kumar, A., Singh, K., Mishra, A. K., Singh, S., & Singh, S. (2024). Cholesterol absorption inhibition by some nutraceuticals. *Recent Advances in Food, Nutrition & Agriculture*, 16(1), 2–11. <https://doi.org/10.2174/012772574X285280240220065812>
11. Singh, S., Chaurasia, A., Rajput, D. S., & Gupta, N. (2024). An overview on mucoadhesive buccal drug delivery systems & approaches: A comprehensive review. *African Journal of Biological Sciences (South Africa)*, 6(5), 522–541, DOI: 10.33472/AFJBS.6.5.2024.522-541
12. Kumar, S., Singh, S., Rajput, D., Sharma, B., Chaturvedi, K., Singh, N., Saha, S., Singh, K., & Mukherjee, S. (2024). Pharmacological approaches and herbal interventions for Alzheimer's disease. *The Natural Products Journal*, 14(8), Article e220124225945. <https://doi.org/10.2174/0122103155275266231123090138>
13. Ravikkumar VR, Patel BD, Rathi S, Parthiban S, Upadhye MC, Shah AM, Rehan SSA, Samanta S, Singh S. Formulation and Evaluation of Drumstick Leaves Tablet as An Immunomodulator. *Zhongguo Ying Yong Sheng Li Xue Za Zhi*. 2024 Jun 21;40:e20240004. doi: 10.62958/j.cjap.2024.004. PMID: 38902996.
14. Sharma, A., Bara, G., Keshamma, E., Sharma, B., Singh, S., Singh, S. P., Parashar, T., Rathore, H. S., Sarma, S. K., & Rawat, S. (2023). Cancer biology and therapeutics: A contemporary review. *Journal of Cardiovascular Disease Research*, 14(10), 1229-1247.
15. Dewangan, H. K., Singh, S., Mishra, R., & Dubey, R. K. (2020). A review on application of nanoadjuvant as delivery system. *International Journal of Applied Pharmaceutics*, 12(4), 24–33. <https://doi.org/10.22159/ijap.2020v12i4.36856>
16. Singh S, Chaurasia A, Gupta N, Rajput DS. Effect of Formulation Parameters on Enalapril Maleate Mucoadhesive Buccal Tablet Using Quality by Design (QbD) Approach. *Zhongguo Ying Yong Sheng Li Xue Za Zhi*. 2024 Jun 27;40:e20240003. doi: 10.62958/j.cjap.2024.003. PMID: 38925868.